Duvelisib’s mechanism of action

Duvelisib (Duvelisib) is a new type of leukocyte signaling pathway inhibitor, belonging to the category of phospholipaseC (PLC)PLC span>-γ and phospholipase D (PLD) inhibitors treat a variety of leukemias and lymphomas through their unique mechanisms of action.

The main mechanisms of action of duvelisel include:

1.PI3KInhibition: PI3K (Phosphatidylinositol3kinase) is a key molecule in cell signaling pathways, involved in regulating cell growth, differentiation, survival and movement. Duvelicet blocks the activation of this signaling pathway by inhibiting multiple isoforms of PI3K, thereby inhibiting the abnormal growth and spread of leukemia and lymphoma cells.

2.BCell signaling pathway inhibition: Duvelicet also reduces BBcell signaling pathways. >Activity in cellular lymphomas, includingCLL (chronic lymphocytic leukemia) and NHL (non-Hodgkin lymphoma). This helps control the progression of these diseases.

3.TCell signaling pathway inhibition: For patients with T cell lymphoma (ATLL/CTCL), duveliced can also inhibit the abnormal activity of T cells, reduce symptoms and extend survival time.

In general, duvelicet interferes with the abnormal growth and spread of leukemia and lymphoma cells through multiple mechanisms, thereby achieving therapeutic effects. The drug's simultaneous inhibition of multiple signaling pathways makes it potentially effective in the treatment of certain types of leukemia and lymphoma, providing a new treatment option especially for patients who are not suitable for or unable to benefit from traditional treatments. Patients should use duvelised under the guidance of a physician to ensure optimal therapeutic effects and minimize adverse reactions.

The original drug of Duvelisel Capsules has been launched in China, but it is not covered by medical insurance. Patients can buy it domestically at a price of more than 20,000 yuan. For specific prices, please consult the local hospital pharmacy.